Biochemical and Histopathological Evaluation of Systemic and Ocular Toxicity of Favipiravir in Rats

Abstract

Purpose: Favipiravir used against COVID-19 is an antiviral drug that causes adverse reactions such as hyperuricemia, liver damage and hematopoetic toxicity. The aim of the study was to investigate the systemic and ocular side-effects of favipiravir in rats, for the first time. Materials and Methods: A total of 18 albino male Wistar rats were used in the study. The rats were divided into 3 groups as the healthy group (HG), the group given 50 mg/kg/day favipiravir (FAV50), and the group given 200 mg/kg/day favipiravir (FAV200). These doses were given to the experimental groups for one week. At the end of the experiment histopathological examinations were performed on the conjunctiva and sclera of the eye. In addition, malondialdehyde (MDA), total glutathione (tGSH), superoxide dismutase (SOD), interleukin-1β (IL-1β) and tumor necrosis factor alpha (TNF-α) levels were measured in blood samples taken from rats. Results: Compared to HG, the MDA (1.37 ± 0.61 vs 4.82 ± 1.40 µmol/ml), IL-1β (2.52 ± 1.14 vs 6.67 ± 1.99 pg/ml) and TNF-α levels (3.28 ± 1.42 vs 8.53 ± 3.06 pg/ml) of the FAV200 group were higher. The levels of tGSH (7.58 ± 1.98 vs 2.50 ± 0.98 nmol/ml) and SOD (13.63 ± 3.43 vs 3.81 ± 1.43 U/ml) the FAV200 group were lower than the HG (p < 0.05, for all). The degree of damage to the cornea and sclera of the FAV200 group was quite high according to HG (p < 0.001). Conclusion: Favipiravir can cause damage to rat conjunctiva and sclera by increasing oxidant stress and inflammation at high dose.